Gabapentin
Product Images NDC 16590-104

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 16590-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 800mg Label Image (Gabapentin 800mg Label)

Label for Gabapentin 800mg tablets, containing 60 tablets per package, distributed by STAT RX USA LLC in Gainesville, GA. The label indicates the product is generic for Neurontin and each tablet contains 800mg of gabapentin. Manufacturer details include Caraco Pharm Labs, Ltd. in Detroit, MI. The label includes dosage and storage instructions, lot and expiration information, and a warning to keep out of reach of children.*

FDA Label Image

Gabapentin-fig01 (Gabapentin Fig01)

A line graph depicting weekly mean pain scores over eight weeks for gabapentin 3600 mg/day versus placebo. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin is associated with a decreasing mean pain score from baseline to week 8, while placebo remains relatively stable. Statistical significance (p < 0.01) is noted at multiple time points favoring gabapentin.*

FDA Label Image

Gabapentin-fig02 (Gabapentin Fig02)

A line graph depicting weekly mean pain scores over seven weeks for placebo and two dosages of gabapentin (1800 mg/day and 2400 mg/day). The x-axis shows weeks from baseline to week 7, and the y-axis represents mean pain score from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a greater reduction in mean pain scores compared to placebo over time.*

FDA Label Image

Gabapentin-fig03 (Gabapentin Fig03)

A bar chart comparing the percentage of responders at endpoint (patients with ≥50% reduction in pain score) in two controlled postherpetic neuralgia (PHN) studies. It shows results for placebo (PBO) and different dosages of gabapentin (GBP 1800, 2400, and 3600 mg). The chart highlights significant differences in responder proportions between placebo and gabapentin groups in both studies, with percentages ranging from 12% to 34%.*

FDA Label Image

Gabapentin-fig04 (Gabapentin Fig04)

A scatter plot chart depicting the responder rate difference (%) from placebo by daily dose (mg) in three gabapentin studies (a, b, c) involving patients 12 years or older with partial seizures. The x-axis represents daily dose (600, 900, 1200, 1800 mg), and the y-axis represents difference in responder rate percentage. Different shapes and shading distinguish the three studies.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). The diagram depicts the molecular arrangement relevant to the active ingredient gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.